Please check your internet connection and try again.
## TUSQ-QD
### Overview
TUSQ-QD is a fixed-dose combination product containing **tuberculosis (TB) treatment drugs**. The exact components and strengths can vary, but commonly include isoniazid, rifampin, pyrazinamide, and ethambutol. TUSQ-QD is designed to simplify treatment regimens and improve adherence.
### Primary Indications
Treatment of active **tuberculosis (TB)** caused by *Mycobacterium tuberculosis*.
### Adult Dosing
Dosing is typically weight-based and depends on the specific formulation and the phase of TB treatment (intensive or continuation).
* **Intensive Phase:** Dosing varies based on formulation. For example, a common regimen for a 50 kg adult might be one tablet daily. Consult local TB treatment guidelines for specific formulations and weight-based dosing.
* **Continuation Phase:** Dosing is often reduced and may involve different formulations or individual drugs. Consult local TB treatment guidelines.
### Pediatric Dosing
Dosing is weight-based and depends on the formulation. Pediatric formulations may be available. **Consult local TB treatment guidelines and pediatric TB treatment resources for specific dosing.**
### Dose Adjustments
* **Renal Impairment:** Dose adjustments may be necessary, particularly for ethambutol. Consult specific drug monographs and local guidelines.
* **Hepatic Impairment:** Caution is advised. Dose reduction or discontinuation may be required. **Close monitoring of liver function is essential.**
### Contraindications
* Hypersensitivity to any component of the medication.
* Severe hepatic disease.
* Concurrent use with certain medications (see Key Drug Interactions).
### Adverse Effects
* **Hepatotoxicity:** This is a serious concern with multiple components. Monitor liver function tests.
* **Gastrointestinal upset:** Nausea, vomiting, abdominal pain.
* **Peripheral neuropathy:** More common with isoniazid. Consider pyridoxine supplementation.
* **Ocular toxicity:** Blurred vision, decreased visual acuity, and red-green color blindness (ethambutol).
* **Rash, fever, arthralgias.**
* **Blood dyscrasias.**
* **Urine discoloration** (orange/red) due to rifampin.
### Key Drug Interactions
* **CYP450 Interactions:** Rifampin is a potent inducer of CYP enzymes, affecting the metabolism of many drugs (e.g., oral contraceptives, anticoagulants, antifungals, anticonvulsants, protease inhibitors, immunosuppressants).
* **Antacids:** May decrease absorption of rifampin. Separate administration.
* **Probenecid:** May increase plasma concentrations of ethambutol.
* **Isoniazid-induced neuropathy:** Risk increased with concurrent use of other neurotoxic agents.
### Monitoring
* **Liver function tests (LFTs):** Baseline and periodically throughout treatment.
* **Visual acuity and color discrimination:** Baseline and periodically if ethambutol is included.
* **Renal function tests.**
* **Complete blood count (CBC).**
* **Sputum microscopy and culture:** To assess treatment response.
* **Adherence:** Crucial for successful TB treatment.
### Clinical Pearls
* TUSQ-QD simplifies multi-drug regimens and improves adherence, but requires careful weight-based dosing and monitoring.
* Always consult current national or local TB treatment guidelines for specific dosing recommendations and management of adverse events.
* Hepatotoxicity is a significant risk; patients should be educated to report signs of liver dysfunction (jaundice, dark urine, fatigue, abdominal pain) immediately.
* Consider pyridoxine supplementation, especially for patients at risk of peripheral neuropathy (e.g., diabetics, alcoholics, pregnant women).
* Advise patients about urine discoloration and potential staining of contact lenses with rifampin.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and institutional guidelines before making treatment decisions. Dosing and recommendations may vary based on patient-specific factors and evolving clinical guidelines.
